NEW YORK, NY / ACCESSWIRE / April 10, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
AAN Shareholders Click Here: https://www.zlk.com/pslra-1/aarons-inc-loss-form?prid=5991&wire=1
CAN Shareholders Click Here: https://www.zlk.com/pslra-1/canaan-inc-loss-form?prid=5991&wire=1
INO Shareholders Click Here: https://www.zlk.com/pslra-1/inovio-pharmaceuticals-inc-loss-form?prid=5991&wire=1
* ADDITIONAL INFORMATION BELOW *
Aarons, Inc. (NYSE:AAN)
AAN Lawsuit on behalf of: investors who purchased March 2, 2018 - February 19, 2020
Lead Plaintiff Deadline : April 28, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/aarons-inc-loss-form?prid=5991&wire=1
According to the filed complaint, during the class period, Aarons, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Aaron's had inadequate disclosure controls, procedures, and compliance measures; (ii) consequently, the operations of Aaron's Progressive Leasing ("Progressive") and Aaron's Business ("AB") segments were in violation of the Federal Trade Commission ("FTC") Act and/or relevant FTC regulations; (iii) consequently, Aaron's earnings from those segments were partially derived from unlawful business practices and were thus unsustainable; (iv) the full extent of Aaron's liability regarding the FTC's investigation into its Progressive and AB segments, Aaron's noncompliance with the FTC Act, and the likely negative consequences of all the foregoing on the Company's financial results; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.
Canaan Inc. (NASDAQ:CAN)
CAN Lawsuit on behalf of: investors who purchased publicly traded securities of Canaan, including its American Depository Shares pursuant and/or traceable to the Company's registration statement and related prospectus issued in connection with the Company's November 20, 2019 initial public offering.
Lead Plaintiff Deadline : May 4, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/canaan-inc-loss-form?prid=5991&wire=1
According to the filed complaint, (1) the purported "strategic cooperation" was actually a transaction with a related party; (2) the company's financial health was worse than what was actually reported; (3) the company had recently removed numerous distributors from its website just prior to the initial public offering, many of which were small or suspicious businesses; and (4) several of the Company's largest Chinese clients in prior years were clients who were not in the Bitcoin mining industry and, thus, would likely not be repeat customers.
Inovio Pharmaceuticals, Inc. (NASDAQ:INO)
INO Lawsuit on behalf of: investors who purchased February 14, 2020 - March 9, 2020
Lead Plaintiff Deadline : May 12, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/inovio-pharmaceuticals-inc-loss-form?prid=5991&wire=1
According to a filed complaint, throughout the class period, defendants made misleading statements about the company's development of a purported vaccine for the novel coronavirus, artificially inflating the company's share price and resulting in significant investor losses.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: Levi & Korsinsky, LLP
View source version on accesswire.com: